ATD was present in some over-the-counterbodybuilding supplements until 2009 as well as Topical ATD solutions that work transdermally. The product was developed and commercialized in the dietary supplement market place by industry journeyman, Bruce Kneller who holds a United States Patent for use of the compound and related compounds (#7,939,517) and Gaspari Nutrition. ATD has many names in sports supplements including: 1,4,6 etiollochan-dione, 3, 17-keto-etiochol-triene, androst-1,4,6-triene-3,17-dione and many others. These all refer to CAS# 633-35-2.
ATD may cause a positive test for the anabolic steroid Boldenone, of which it is a possible metabolite and production contaminant. ATD is also prohibited in amateur and professional sports which forbids aromatase inhibitors.
^Covey, DF; Hood, WF (1981). "Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity". Endocrinology. 108 (4): 1597–9. doi:10.1210/endo-108-4-1597. PMID7472286.
^Parr MK, Fusshöller G, Schlörer N, Opfermann G, Piper T, Rodchenkov G, Schänzer W (2009). "Metabolism of androsta-1,4,6-triene-3,17-dione and detection by gas chromatography/mass spectrometry in doping control". Rapid Commun Mass Spectrom. 23 (2): 207–18. doi:10.1002/rcm.3861. PMID19089863.
Ellinwood WE, Hess DL, Roselli CE, Spies HG, Resko JA (1984). "Inhibition of aromatization stimulates luteinizing hormone and testosterone secretion in adult male rhesus monkeys". J. Clin. Endocrinol. Metab. 59 (6): 1088–96. doi:10.1210/jcem-59-6-1088. PMID6541658.